ALL AIDSLINE ASK THE DOC CONFERENCES --5th IAS HIV Pathog & Treat --4th IAS HIV Pathog & Treat --3rd IAS HIV Pathog & Treat --2nd IAS HIV Pathog & Treat --1st IAS HIV Pathog & Treat -Intl AIDS Conferences --17th Int Conf AIDS: Toronto (2006) --16th Int Conf AIDS: Toronto (2006) --15th Int Conf AIDS: Bangkok (2004) --14th Int Conf AIDS: Barcelona (2002) --13th Int Conf AIDS: Durban (2000) --12th Int Conf AIDS: Geneva (1998) --11th Int Conf AIDS: Vancouver --10th Int Conf AIDS: Yokohoma --9th Int Conf AIDS: Berlin --8th Int Conf AIDS: Amsterdam --7th Int Conf AIDS: Florence --6th Int Conf AIDS: San Franciso --5th Int Conf AIDS: Montreal --4th Int Conf AIDS: Stockholm --3rd Int Conf AIDS: Washington --2nd Int Conf AIDS: Paris --1st Int Conf AIDS: Atlanta --9th Intl Cong. Drug Therapy: Glasgow 2008 --8th Intl Cong. Drug Therapy: Glasgow 2006 --7th Intl Cong. Drug Therapy: Glasgow 2004 --6th Intl Cong. Drug Therapy: Glasgow 2002 --5th Intl Cong Drug Therapy: Glasgow 2000 --3rd Intl Cong Drug Therapy: Glasgow 1996 --2nd Intl Cong Drug Therapy: Glasgow 1994 --10th Lipo: London, UK --9th Lipo: Sydney, Australia --8th Lipo: San Francisco --7th Lipo: Dublin, Ireland --6th Lipo: Washington, DC --5th Lipo: Paris, France --4th Lipo: San Diego --3rd Lipo: Athens, Greece --2nd Lipo: Toronto, Canada --1st Lipo: San Diego --15th Conf Retroviruses Opportunistic Infect --14th Conf Retroviruses Opportunistic Infect --13th Conf Retroviruses Opportunistic Infect --12th Conf Retroviruses Opportunistic Infect --11th Conf Retroviruses Opportunistic Infect --10th Conf Retroviruses Opportunistic Infect --9th Conf Retroviruses Opportunistic Infect --8th Conf Retroviruses Opportunistic Infect --7th Conf Retroviruses Opportunistic Infect --6th Conf Retroviruses Opportunistic Infect --5th Conf Retroviruses Opportunistic Infect --4th Conf Retroviruses Opportunistic Infect --3rd Conf Retroviruses Opportunistic Infect --2nd Conf Retroviruses Opportunistic Infect --1st Conf Retroviruses Opportunistic Infect --2005 Natl HIV Prev Conf --2003 Natl HIV Prev Conf --1999 Natl HIV Prev Conf --18th Intl Wkshop HIV Drug Resistance --17th Intl Wkshop HIV Drug Resistance --16th Intl Wkshop HIV Drug Resistance --15th Intl Wkshop HIV Drug Resistance --14th Intl Wkshop HIV Drug Resistance --13th Intl Wkshop HIV Drug Resistance --12th Intl Wkshop HIV Drug Resistance --11th Intl Wkshop HIV Drug Resistance --3rd Intl Wkshop HIV Drug Resistance --5th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --4th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --1st Intl Wkshop on HIV Drug Resistance & Treatment Strategies --15th British HIV Ass'n Conf 2009 --14th British HIV Ass'n Conf 2008 --13th British HIV Ass'n Conf 2007 --12th British HIV Ass'n Conf 2006 --11th British HIV Ass'n Conf 2005 --10th British HIV Ass'n Conf 2004 -- 9th British HIV Ass'n Conf 2003 -- 8th British HIV Ass'n Conf 2002 -- 7th British HIV Ass'n Conf 2001 --9th European AIDS Conf. --8th European AIDS Conf. FACT SHEETS --AIDS Treatment Data Network LAW NEWS SERVICES --AIDS Daily Summary --Agence France-Presse --Asia Times --Associated Press --Bay Area Reporter --BBC On-Line --Bangkok Post --Business Wire --CATIE --Chicago Tribune --FDA News --Inter Press Service --Integrated Regional Information Network --Los Angeles Times --Mail & Guardian --Miami Herald --Newsday --New Vision --New York Times --OC Weekly --PRNewswire --Reuters --San Francisco Chronicle --San Francisco Examiner --Sunday Times --UNAIDS --United Press International --Voice of America --Wall Street Journal --Washington Blade PUBLICATIONS --ACRIA --AIDS Treatment News --AIDS Weekly Plus --amfAR --Being Alive --BETA --BMC AIDS Res Therapy --CATIE --Emerging Infectious Diseases --Gay Men's Health Crisis --HIV Education Project --HIV Treatment Bulletin --IAPAC --IAVI --MMWR --Project Inform PLOS --PLOS Biology --PLOS Medicine --PLOS One --PLOS Pathogens --RITA --Treatment Action Group --Women Alive TOPICS Your Search for PRO 2000 matched 125 Documents (Page 1 of 5). Results Indexed by relevance.
1.	AEGiS-Health-e: The search for a microbicide continues (100%) Abstract: The search for an effective microbicide has been dealt another blow with disappointing study results from PRO 2000, an early generation microbicide gel that was tested to prevent HIV in women. The results from the four-year trial, which took place in South Africa , Tanzania , ... http://ww2.aegis.org/news/healthe/2009/he091217.html File Name: he091217.html, Size: 27KB, Last Modified: Monday, December 14, 2009 at 3:00:00 PM
2.	AEGiS-IRIN: Microbicide hopes dashed again (100%) Abstract: JOHANNESBURG, 14 December 2009 (PlusNews) - A four-year clinical trial involving nearly 10,000 women in East and Southern Africa has found that the vaginal microbicide gel, PRO 2000, is safe but not effective at preventing HIV infection. The trial, known as MDP 301, found that women who applied a vaginal gel containing ... http://ww2.aegis.org/news/irin/2009/ir091224.html File Name: ir091224.html, Size: 12KB, Last Modified: Monday, December 14, 2009 at 3:00:00 PM
3.	AEGiS-SAPA: Disappointing results for microbicide research (100%) Abstract: New research has concluded that the vaginal microbicide gel, PRO 2000, does not prevent HIV infection in women, a study released on Monday said. The researchers agree that while the results mean the end of the road for PRO 2000 -- and the entire second generation of microbicide formulations -- they are upbeat about nex ... http://ww2.aegis.org/news/sapa/2009/sa091204.html File Name: sa091204.html, Size: 10KB, Last Modified: Monday, December 14, 2009 at 3:00:00 PM
4.	AFRICA: AIDS Virus Prevention Gel Fails in African Trials (100%) Abstract: The largest trial to date of an experimental vaginal microbicide to prevent HIV infection has concluded with no evidence that the once-promising product works, researchers said on Monday. Earlier results presented in February at the Montreal AIDS conference had suggested PRO 2000 could cut HIV transmission by one-third ... http://ww2.aegis.org/news/ads/2009/ad092135.html File Name: ad092135.html, Size: 10KB, Last Modified: Monday, December 14, 2009 at 3:00:00 PM
5.	AEGiS-AIDSWeekly: HIV/AIDS Prevention: Vaginal microbicide phase III trial underway, 10,000 women to be enrolled (100%) Abstract: Indevus Pharmaceuticals, Inc., (IDEV) has initiated a large, international phase III clinical trial of PRO 2000, the company's topical, vaginal microbicide in development for the prevention of sexually transmitted infections, including HIV, herpes, chlamydia and gonorrhea. The trial is being sponsored by the Medical Re ... http://ww2.aegis.org/pubs/aidswkly/2005/aw051106.html File Name: aw051106.html, Size: 12KB, Last Modified: Thursday, May 21, 2009 at 9:26:48 PM
6.	AEGiS-Health-e: Hope in attempts to find alternatives to ARV therapy as a prevention tool (100%) Abstract: A lecture given at the 16th Conference on Retroviruses and Opportunistic Infections (CROI) held in Montreal, Canada , recently highlighted the extent to which Antiretroviral therapy (ARV) has become central to today s attempts to prevent HIV infection. Although the broader topic of the lecture was that of HIV research ... http://ww2.aegis.org/news/healthe/2009/he090310.html File Name: he090310.html, Size: 11KB, Last Modified: Monday, March 16, 2009 at 3:00:00 PM
7.	AEGiS-BAR: Study: Microbicide protects against HIV during sex in women (100%) Abstract: The first successful clinical trial of a microbicide, a topical gel that can protect against HIV during sex, brought a sense of hope and relief to prevention advocates. The news broke last week at the Conference on Retroviruses and Opportunistic Infections in Montreal. PRO 2000 binds to the part of HIV that the virus u ... http://ww2.aegis.org/news/bar/2009/br090205.html File Name: br090205.html, Size: 12KB, Last Modified: Thursday, February 19, 2009 at 7:29:31 PM
8.	AEGiS-Health-e: Vaginal gel blocks HIV - but not enough to be scientific success (100%) Abstract: Candidate microbicide PRO 2000 cuts HIV transmission by 30 percent, falling just short of the one-third required to be deemed a success. But scientists say this trial offers proof that the concept of a vaginal gel to block HIV is possible. For the first time in over a decade of research, a vaginal gel called PRO 2000 h ... http://ww2.aegis.org/news/healthe/2009/he090202.html File Name: he090202.html, Size: 10KB, Last Modified: Tuesday, February 10, 2009 at 3:00:00 PM
9.	AEGiS-PRn: Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study: Results of NIH-sponsored Clinical Trial to be Presented at Retrovirus Conference (100%) Abstract: LEXINGTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating women who received PRO 2000, the Company s candidate vaginal microbicide for HIV prevention, had an approximately 30 ... http://ww2.aegis.org/news/pr/2009/pr090212.html File Name: pr090212.html, Size: 17KB, Last Modified: Monday, February 09, 2009 at 3:00:00 PM
10.	AEGiS-Natl HIV Prev Conf 1999 [650]: PRO 2000 gel, a candidate topical microbicide, can inhibit vaginal simian/human immunodeficiency virus infection in rhesus macaques. (100%) Abstract: PRO 2000 Gel is a candidate topical microbicide designed to prevent the sexual transmission of HIV and other STD pathogens. Laboratory studies have shown that the naphthalene sulfonate polymer PRO 2000 is active in vitro against HIV-1, HIV-2, herpes simplex viruses (HSV-1 and HSV-2), human ... http://ww2.aegis.org/conferences/nhivpc/1999/650.html File Name: 650.html, Size: 9KB, Last Modified: Saturday, January 10, 2009 at 12:19:36 AM
11.	[ThPe0019] THE CANDIDATE POLYANIONIC MICROBICIDE, PRO 2000, INHIBITS ENTRY MEDIATED BY DIVERSE HIV-1 ENVELOPES (100%) Abstract: PRO 2000 is active against diverse HIV-1 Env-pseudotyped viruses. Although PRO 2000 has been postulated to interact with the V3 loop in a charge dependent manner, it inhibits HIV-1 gp120 across a spectrum of V3 loop charges and gp120 N-glycosylation patterns. Given that topical microbicides are currently in clinical tr ... http://ww2.aegis.org/conferences/iac/2006/thpe0019.html File Name: thpe0019.html, Size: 9KB, Last Modified: Wednesday, April 23, 2008 at 8:00:00 AM
12.	AEGiS-PRn: Indevus Pharmaceuticals Provides Update on PRO 2000 Program (100%) Abstract: LEXINGTON, Mass., Feb. 15 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that they have been advised by the United Kingdom s Medical Research Council (MRC) that after review of data from the Phase III clinical trial of PRO 2000, the Company s candidate vaginal microbicide for HIV ... http://ww2.aegis.org/news/pr/2008/pr080248.html File Name: pr080248.html, Size: 13KB, Last Modified: Friday, February 15, 2008 at 3:00:00 PM
13.	PRO 2000, Under Development by Indevus, Shown to Inhibit HIV and Herpes Simplex Virus Infection Following Human Administration (100%) Abstract: -- Data Marks First Proof of Anti-Viral Activity by a Microbicide after Human Application LEXINGTON, Mass.-- Findings presented at the 12th Conference on Retroviruses and Opportunistic Infections demonstrated that PRO 2000, a candidate topical microbicide under development by Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV ... http://ww2.aegis.org/news/bw/2005/bw050218.html File Name: bw050218.html, Size: 12KB, Last Modified: Tuesday, March 06, 2007 at 5:34:44 PM
14.	Indevus Announces Selection of PRO 2000 by Microbicide Development Programme as Sole Agent for Full-Scale, International Anti-HIV Trials (100%) Abstract: LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. today announced that the Microbicide Development Programme (MDP) has selected PRO 2000, the Company s microbicide under development to prevent sexual infection by HIV, as the sole agent to be tested in full-scale clinical trials due to start next year in a number of Afr ... http://ww2.aegis.org/news/bw/2004/bw040908.html File Name: bw040908.html, Size: 10KB, Last Modified: Tuesday, March 06, 2007 at 5:34:33 PM
15.	(BW) (PROCEPT)(PRCTC) Procept Presents Findings On Topical Microbicide At 12th World AIDS Conference; In Vitro and In Vivo Experiments Suggest That PRO 2000 Gel Could Protect Against a Variety of Sexually Transmitted Diseases (100%) Abstract: GENEVA--(BUSINESS WIRE)--July 1, 1998-- Procept, Inc. (Nasdaq:PRCTC) today presented findings at the 12th World AIDS Conference in Geneva showing that its vaginal microbicide, PRO 2000 Gel, may provide protection against a number of sexually transmitted diseases. In a poster presentation, Procept scientists and colleag ... http://ww2.aegis.org/news/bw/1998/bw980701.html File Name: bw980701.html, Size: 12KB, Last Modified: Tuesday, March 06, 2007 at 5:33:07 PM
16.	(BW) Procept's PRO 2000 Gel Found Safe And Well Tolerated In Second Clinical Trial Results of London Phase I Study Presented at Retrovirus Conference (100%) Abstract: CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 2, 1998-- Procept, Inc. (Nasdaq:PRCT - news) today is presenting the results of its second Phase I clinical trial of PRO 2000 Gel at the 5th Conference on Retroviruses and Opportunistic Infections in Chicago. PRO 2000 Gel, the Company s lead drug candidate, is designed as a femal ... http://ww2.aegis.org/news/bw/1998/bw980201.html File Name: bw980201.html, Size: 9KB, Last Modified: Tuesday, March 06, 2007 at 5:33:02 PM
17.	(BW) Patient Enrollment Initiated In Phase I/II Clinical Trial Of Procept's Pro 2000 Once-Daily Formulation For HIV (100%) Abstract: CAMBRIDGE, Mass.--(HealthWire)--May 16, 1996--Procept, Inc. (Nasdaq: PRCT) today announced that the Company has initiated enrollment of patients in a new Phase I/II clinical trial in Europe to evaluate the safety and efficacy of PRO 2000 for the treatment of human immunodeficiency virus type I (HIV-1) infection. The st ... http://ww2.aegis.org/news/bw/1996/bw960505.html File Name: bw960505.html, Size: 10KB, Last Modified: Tuesday, March 06, 2007 at 5:32:28 PM
18.	(BW) Procept Initiates New Phase I/II Clinical Trial For Pro 2000 In HIV-Positive Patients (100%) Abstract: CAMBRIDGE, Mass.--(Health Wire)--January 9, 1996--Procept, Inc. (Nasdaq: PRCT) today announced that the Company has received approval to initiate a new Phase I/II clinical trial to evaluate the safety and efficacy of PRO 2000 for the treatment of human immunodeficiency virus type I (HIV-1) infection. The study will use ... http://ww2.aegis.org/news/bw/1996/bw960104.html File Name: bw960104.html, Size: 9KB, Last Modified: Tuesday, March 06, 2007 at 5:32:20 PM
19.	UNITED STATES: Experimental Vaginal Gel Inhibits HIV and HSV (100%) Abstract: In a new report, researchers document that vaginal application of the PRO 2000 gel exerts activity against HIV and herpes simplex virus (HSV). The synthetic compound prevents HIV s entry into cells by interacting with proteins on the surface of the virus. Its effects against HIV and HSV had been shown previously in cel ... http://ww2.aegis.org/news/ads/2006/ad060162.html File Name: ad060162.html, Size: 11KB, Last Modified: Friday, January 27, 2006 at 3:00:00 PM
20.	[WePe10.8P09] PHASE I SAFETY AND ACCEPTABILITY STUDY OF 0.5% PRO 2000 VAGINAL GEL AMONG HIV UN-INFECTED WOMEN IN PUNE, INDIA (100%) Abstract: Twice-daily use of 0.5% PRO 2000 Gel appears to be safe in HIV-uninfected women from Pune, India. Acceptability was high among all participants. Safety and acceptability will continue to be monitored carefully in ongoing efficacy trials. ... http://ww2.aegis.org/conferences/iashivpt/2005/wepe10-8p09.html File Name: wepe10-8p09.html, Size: 9KB, Last Modified: Monday, July 25, 2005 at 6:29:23 AM
21.	Phase II Trial with PRO 2000 to Prevent HIV Transmission Begins in Africa (100%) Abstract: Indevus Pharmaceuticals Inc. announced the initiation of a phase II clinical trial in Kampala, Uganda , to assess the safety of PRO 2000, a topically administered vaginal microbicide designed to prevent HIV infection. The randomized, double-blind, placebo-controlled trial will enroll approximately 100 sexually active f ... http://ww2.aegis.org/news/ads/2003/ad031695.html File Name: ad031695.html, Size: 10KB, Last Modified: Wednesday, August 20, 2003 at 3:00:00 PM
22.	AEGiS-14IAC: PRO 2000 achieves potentially protective levels against HIV in cervico-vaginal lavage in a vaginal microbicide safety study. (100%) Abstract: <p><b>BACKGROUND:</b> We determined concentrations of PRO 2000, a candidate vaginal microbicide, in cervico-vaginal secretions and plasma within a phase I study of this agent. </p> <p><b>METHODS:</b> Women self-administered a 2g intravaginal dose of either 4%, 0.5% or 0% PRO 2000 gel, twice on day 0 and then daily f ... http://ww2.aegis.org/conferences/iac/2002/moped3647.html File Name: moped3647.html, Size: 7KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
23.	AEGiS-14IAC: Safety and tolerance of PRO 2000 Gel, a candidate vaginal microbicide, in different populations. (100%) Abstract: <p><b>BACKGROUND:</b> The safety and tolerance of PRO 2000 Gel, a candidate vaginal microbicide for HIV/STD prevention, was assessed in healthy, low-risk women and asymptomatic HIV+ women recruited in four countries. </p> <p><b>METHODS:</b> In Belgium and the UK, 73 healthy, sexually abstinent volunteers were enroll ... http://ww2.aegis.org/conferences/iac/2002/moped3652.html File Name: moped3652.html, Size: 8KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
24.	[256] THE SAFETY AND TOLERABILITY OF PRO2000, A NOVEL VAGINAL MICROBICIDE IN SEXALLY ACTIVE HIV- AND ABSTIENT HIV+ WOMEN (100%) Abstract: PRO 2000 Gel is safe and well-tolerated by HIV+ and sexually active HIV- women. ... http://ww2.aegis.org/conferences/iashivpt/2001/256.html File Name: 256.html, Size: 6KB, Last Modified: Monday, July 09, 2001 at 6:29:23 AM
25.	AEGiS-08CROI: Efficacy of PRO 2000 gel in a macaque model for vaginal HIV transmission. (100%) Abstract: Background. PRO 2000 Gel is a candidate vaginal microbicide designed to prevent the sexual transmission of HIV and other STD pathogens. The antimicrobial compound PRO 2000 is active in- vitro against HIV-1, HIV-2, herpes simplex viruses, chlamydia and gonococci. Moreover, intravaginally applied PRO 2000 Gel has been sh ... http://ww2.aegis.org/conferences/croi/2001/721.html File Name: 721.html, Size: 6KB, Last Modified: Sunday, February 04, 2001 at 8:12:04 PM
26.	AEGiS-13IAC: Molecular evaluation of the anti-HIV activity of PRO 2000, a candidate topical microbicide. (100%) Abstract: Backgound: PRO 2000 is a naphthalene sulfonate polymer under development as a topical microbicide to prevent HIV transmission. In earlier studies, PRO 2000 inhibited HIV infection of cells and HIV-mediated cell-cell fusion at concentrations > 1 m g/mL, but caused negligible cytotoxicity at 100 m g/mL. <p><b>OBJECTIVE ... http://ww2.aegis.org/conferences/iac/2000/wepea4115.html File Name: wepea4115.html, Size: 7KB, Last Modified: Sunday, July 09, 2000 at 8:12:04 PM
27.	PRO 2000 gel, a candidate topical microbicide, can inhibit vaginal simian/human immunodeficiency virus infection in rhesus macaques. (100%) Abstract: BACKGROUND/OBJECTIVES: PRO 2000 Gel is a candidate topical microbicide designed to prevent the sexual transmission of HIV and other STD pathogens. Laboratory studies have shown that the naphthalene sulfonate polymer PRO 2000 is active in vitro against HIV-1, HIV-2, herpes simplex viruses (HSV-1 and HSV-2), human ... http://ww2.aegis.org/aidsline/2000/may/a0050989.html File Name: a0050989.html, Size: 11KB, Last Modified: Sunday, May 28, 2000 at 8:12:04 PM
28.	AEGiS-Reuters: Procept gel fights HIV infection in monkey study (100%) Abstract: CAMBRIDGE, Mass., March 11 (Reuters) - Procept, Inc. (Nasdaq:PRCT - news) said Thursday that its PRO 2000 Gel topical microbicide has shown in studies on monkeys evidence of protection from vaginal human immunodeficiency virus (HIV) transmission. The company said results from a small study indicated that PRO 2000 Gel r ... http://ww2.aegis.org/news/re/1999/re990306.html File Name: re990306.html, Size: 8KB, Last Modified: Thursday, March 11, 1999 at 3:00:00 PM
29.	PRO 2000 gel, a potential topical microbicide for HIV prevention, can block infection by other sexually transmitted disease pathogens. (100%) Abstract: BACKGROUND: PRO 2000 is a 5-kD naphthalene sulfonate polymer that shows broad activity against HIV-1 in vitro. The compound is being developed as a topical microbicide to prevent transmission of HIV-1 and other sexually transmitted disease (STD) pathogens. Vaginal gels containing up to 4.0% PRO 2000 were well tolerate ... http://ww2.aegis.org/aidsline/1998/dec/m98c3405.html File Name: m98c3405.html, Size: 10KB, Last Modified: Tuesday, December 29, 1998 at 6:29:23 AM
30.	Safety and tolerability of PRO 2000 gel: a potential vaginal virucide. (100%) Abstract: Objective: To evaluate the safety and tolerability of intravaginal PRO 2000 gel at two concentrations in healthy female volunteers. Background: PRO 2000 is a naphthalene sulphonate polymer which effectively inhibits HIV in vitro by blocking initial binding and membrane fusion events. It has similar activity against bo ... http://ww2.aegis.org/aidsline/1998/jun/m9860709.html File Name: m9860709.html, Size: 9KB, Last Modified: Monday, June 29, 1998 at 6:29:23 AM
	1 2 3 4 5 Next
	AEGiS Search Engine. Status: The Index is up to date.